New Assay, New Cohorts—Plasma p-Tau181 Looks Even Better
At AAT-ADPD, researchers report how they built on prior reports that a person’s blood level of p-tau181 tells if they have Alzheimer’s.
NEWS
Low-Dose Aspirin Does Not Prevent AD, or Slow Cognitive Decline
A trial of nearly 20,000 participants found no benefit over five years.
A Phospho-Tau Plasma Assay for Alzheimer’s?
Two papers report that phosphorylated tau in the blood distinguishes people with AD from healthy controls and from people with frontotemporal and vascular dementias.
A ‘Perfect Storm’ for Families Grappling with Dementia
From caregivers going it alone to understaffed nursing homes on lockdown, people with neurodegenerative disease and their caregivers are feeling enormous strain from the novel coronavirus. They are adapting to the new normal with technology.
Coronavirus Takes Its Toll on Alzheimer’s Clinical Studies
Most observational cohorts are on pause, and many clinical trials have stopped dosing. The long-term effects on the integrity of AD studies are unclear.
Social Distancing Shutters Alzheimer’s Research
With experiments and careers on hold, scientists working from home are turning to virtual lab meetings and journal clubs to keep up morale.
Dementia Research Institute to Double U.K. Coronavirus Testing
United Kingdom’s DRI pivots to fight COVID-19. The facility could test 10,000 samples per day.
Stress-Associated Protein Modulates γ-Secretase to Make More Aβ
Under diabetic conditions, SERP1 binds secretase subunit, cranking up cleavage of APP but not Notch. The finding offers a mechanistic link between diabetes and Alzheimer’s.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome F. Hoffmann-La Roche, joining our other exhibitors — Biogen, BioLegend, Dash Genomics, Inc., Abcam, BrainXell, and the Jackson Laboratory.
SPOTLIGHT
COVID-19 Shutters Labs, Clinics, Heaps Stress on Patients
As the new coronavirus rages around the globe, taking lives and bringing down economies, the research community’s collective project to find better treatments for neurodegenerative disease is not spared, either. Research institutes are shuttered, essential mouse strains and cell lines are in danger, and clinical trials and observation studies are having to pause dosing and evaluations. For patients and the carers, social distancing adds enormous stress to already difficult lives. But necessity is the mother of invention and, as in other walks of life these days, the neurodegeneration community is rising to the occasion by moving much of its work online–perhaps even to some lasting benefit. Read accounts by Tom Fagan, Madolyn Rogers, and Jessica Shugart about what COVID-19 is doing to our field, and this story about how the U.K. DRI quickly tried to help out.
Join The Conversation
Professional Resources
New in last 7 days
-
Grants
- New Items: 7
- Total Items: 527
-
Jobs
- Total Items: 84
-
Conference Calendar
- New Items: 8
- Total Items: 94
- Member Directory
Latest Comments